Britain’s GSK to buy Affinivax in $3.3 billion deal By Reuters

[ad_1]

© Reuters. FILE PHOTO: Signage for GlaxoSmithKline is seen on it’s offices in London, Britain, March 30, 2016. REUTERS/Toby Melville/File Photo

(Reuters) – British drugmaker GSK said on Tuesday it would pay up to $3.3 billion to acquire privately held biopharmaceutical firm Affinivax, as it seeks to bolster its vaccine pipeline.

[ad_2]

News Source: www.investing.com